Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Elevation of ADP-ribosylation as an indicator of mononuclear leucocyte responsiveness in breast cancer patients treated with tamoxifen

Pero, Ronald W. LU ; Olsson, Håkan LU orcid ; Killander, Fredrika LU and Troll, Walter (1992) In European Journal of Cancer 28(11). p.1803-1806
Abstract

82 women who had had surgery for removal of breast cancer were randomised during the primary care period before initiation of any chemotherapy or radiotherapy into two groups: no drug treatment (n = 40) and 20 mg tamoxifen per day for 2 years (n = 42). Mononuclear leucocyte (MNL) fractions from blood samples were collected during the first 368 days of the study and ADP-ribosylation was quantified. Tamoxifen treatment resulted in a dose-duration increase in ADP-ribosylation. This was true even after adjustment for covariates such as age, smoking habits, oestrogen use, menstruation and tumour size. These data suggest that part of the antitumour effects of tamoxifen treatment in vivo relates to an enhanced immune cell responsiveness, as... (More)

82 women who had had surgery for removal of breast cancer were randomised during the primary care period before initiation of any chemotherapy or radiotherapy into two groups: no drug treatment (n = 40) and 20 mg tamoxifen per day for 2 years (n = 42). Mononuclear leucocyte (MNL) fractions from blood samples were collected during the first 368 days of the study and ADP-ribosylation was quantified. Tamoxifen treatment resulted in a dose-duration increase in ADP-ribosylation. This was true even after adjustment for covariates such as age, smoking habits, oestrogen use, menstruation and tumour size. These data suggest that part of the antitumour effects of tamoxifen treatment in vivo relates to an enhanced immune cell responsiveness, as indicated by the increased MNL ADP-ribosylation.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
28
issue
11
pages
4 pages
publisher
Elsevier
external identifiers
  • scopus:0026744650
  • pmid:1389513
ISSN
0959-8049
DOI
10.1016/0959-8049(92)90007-O
language
English
LU publication?
yes
id
04c90629-578a-421b-a5d9-125990226bea
date added to LUP
2019-05-28 16:19:16
date last changed
2024-01-01 08:11:14
@article{04c90629-578a-421b-a5d9-125990226bea,
  abstract     = {{<p>82 women who had had surgery for removal of breast cancer were randomised during the primary care period before initiation of any chemotherapy or radiotherapy into two groups: no drug treatment (n = 40) and 20 mg tamoxifen per day for 2 years (n = 42). Mononuclear leucocyte (MNL) fractions from blood samples were collected during the first 368 days of the study and ADP-ribosylation was quantified. Tamoxifen treatment resulted in a dose-duration increase in ADP-ribosylation. This was true even after adjustment for covariates such as age, smoking habits, oestrogen use, menstruation and tumour size. These data suggest that part of the antitumour effects of tamoxifen treatment in vivo relates to an enhanced immune cell responsiveness, as indicated by the increased MNL ADP-ribosylation.</p>}},
  author       = {{Pero, Ronald W. and Olsson, Håkan and Killander, Fredrika and Troll, Walter}},
  issn         = {{0959-8049}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{11}},
  pages        = {{1803--1806}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Elevation of ADP-ribosylation as an indicator of mononuclear leucocyte responsiveness in breast cancer patients treated with tamoxifen}},
  url          = {{http://dx.doi.org/10.1016/0959-8049(92)90007-O}},
  doi          = {{10.1016/0959-8049(92)90007-O}},
  volume       = {{28}},
  year         = {{1992}},
}